ルでの解析-. 第 45 回日本移植学会総会, 東京 2009. 9. 16-18

40) 伊禮俊充, 田中友加, 尾上隆司, 井手健太郎, 大平真裕, 五十嵐友香, 田原裕之, 番匠谷将孝, Basnet Nabin, 田澤宏文, 大段秀樹:B 細胞—NK 細胞間シグナル伝達制御による抗体性拒絶反応抑制の可能性. 第 45 回日本移植学会総会, 東京, 2009. 9. 16-18

41) 田原裕之, 井手健太郎, Basnet Nabin, 田中友加, 竹松　弘, 小堤保則, 大段秀樹:異種移植における異種抗原 N-Glycolylneuraminic acid (NeuGc)の役割第 45 回日本移植学会総会, 東京, 2009. 9. 16-18

42) バスネット・ナビン, 田原裕之, 井手健太郎, 田中友加, 竹松　弘, 小堤保則, 大段秀樹:N-Glycolylneuraminic acid is recognised by naturally occurring cytotoxic human xenoantibodies. 第 45 回日本移植学会総会, 東京, 2009. 9. 16-18

43) 田澤宏文, 伊禮俊充, 五十嵐友香, 田中友加, 尾上隆司, 井手健太郎, 田原裕之, 番匠谷将孝, 田代裕尊, 大段秀樹:血液型不適合移植への減感作療法が C 型肝炎の術後再燃に対して与える影響. 第 45 回日本移植学会総会, 東京, 2009. 9. 16-18

44) Doskari Marlen, 大平真裕, 田中友加, 五十嵐友香, 浅原利正, 茶山一彰, 大段秀樹: Therapeutic potential of CD56＋ cells on recurrence of HCC and HCV infection after liver transplantation. 第 45 回日本移植学会総会, 東京, 2009. 9. 16-18

45) 寺岡義布史, 田代裕尊, 井手健太郎, 小林剛, 大下彰彦, 天野尋暢, 板本敏行, 大段秀樹:自己免疫性肝炎に合併した混合型肝癌の生体肝移植例. 第 45 回日本移植学会総会, 東京, 2009. 9. 16-18

G. 知的所有権の取得状況

1. 特許取得

発明者 : 大段秀樹, 伊禮俊充

抗体拒絶反応抑制剤(特願 2009-110887)

厚生労働科学研究費補助金（肝炎等克服緊急対策研究事業）
（分担）研究報告書（平成２１年度）
ヒト肝細胞キメラマウスを用いた治療抵抗性の肝炎に関する研究

ヒト肝細胞キメラマウスを用いた新規抗HCV薬の効果判定

研究分担者　今村道雄　広島大学病院消化器内科　助教

研究要旨： ヒト肝細胞キメラマウスにC型肝炎ウイルス(HCV)陽性患者血清を投与し，HCV感染を惹起した．HCV感染マウスにPhosphorothioate oligonucleotide (PS-ON)を前投与することにより，HCV感染が抑制され，PS-ONはin vivoにおてい感染阻害剤として有用であることが示された．HCV感染マウスに対し，ソヤサポゲノールB誘導体の経口投与単独ではHCV抑制効果を認めなかったが，IFN-αと併用することにより，IFN-αの抗HCV効果を増強させた．HCV感染マウスにProtease inhibitorあるいはRNA polymerase inhibitorを単独投与すると，両薬剤とも抗HCV効果を認めるものの，耐性ウイルス出現によるbreakthroughを発症した．しかし両剤を併用投与することにより，breakthroughの予防，抗ウイルス効果の増強効果を認め，HCVの排除も可能であり，異なるHCV蛋白を標的とるす薬剤を組み合わせることにより，IFN製剤を使用せずともHCVの排除が可能であることが示された．HC感染マウスを用いて種々の抗ウイルス剤の効果判定および新規治療法の開発が可能であった．

A．研究目的

ヒト肝細胞キメラマウスを用いて，新規候補となるHCV感染阻害剤や抗HCV剤のスクリーニング，あるいは種々の薬剤を組み合わせることにより，より有効な抗HCV治療法を開発する．

B．研究方法

1)ヒト肝細胞キメラマウスにHCV陽性ヒト血清を投与し，感染を惹起した．HCV陽性ヒト血清投与前日，投与日，投与1，3，5日後にhuman immunodeficiency virus (HIV) のentry阻害剤であるPhosphorothioate oligonucleotide (PS-ON)を10 mg/kg，腹腔内投与した．ヒト血清投与2週間後にマウス血中HCV RNAを測定し，感染成立の有無を確認した．

2)HCV感染マウスにインターフェロン-αあるいはソヤサポゲノールB誘導体を4週間，単独あるいは併用投与し，マウス血中HCV RNA低下量および肝臓内HCVコア抗原量を測定した．

3) HCV感染マウスに28日間，Protease inhibitorであるtelaprevir (200 mg/kg，1日2回，連日経口投与：)あるいはRNA polymerase inhibitorであるMK-0609 (3 mg/kg，1日2回，連日経口投与：)単独および両者を併用投与し，マウス血中HCV RNA量の測定した．

C．結果

1)Control群では，マウスのHCV感染を7頭

中7頭(100%)に認めたの対し，PS-ON投与群では7頭1頭（14％）のみであり(p=0.001)，PS-ONがin vivoにおいて，HCVの感染阻害に有用であることが示された．
2) 4週間のIFN-α単独投与によりマウス血中HCV RNAは1.9 log低s下した．ソヤサポゲノール B 誘導体単独ではHCV RNAは低下しなかったが，IFN-α/ソヤサポゲノール B 誘導体との併用により4.7 logとIFN-αに比べ有意に低下した(p=0.035)．また投与4週後の肝臓内コア抗原量はIFN-α/ソヤサポゲノール B 誘導体併用投与群で最も低かった．
3)Telaprevir，MK-0609両剤とも単独で著明な抗ウイルス効果を認めたが，耐性ウイルスの出現により投与中，breakthroughを生じた．両剤を併用投与することにより，耐性ウイルスの出現は予防され，より強い抗ウイルス効果を認め，さらに観察した投与終了18週後も血中HCV RNAは陰性であり，おそらくHCVは完全排除されたものと思われた．

D．考察

PS-ONはHCV感染阻害に，ソヤサポゲノール B 誘導体はIFN製剤と組み合わせることにより抗HCV薬で有用と思われた．種々のHCV蛋白を標的とした薬剤を組み合わせることにより，IFN製剤を使用せずともHCVの排除が可能となることが示唆された．

E．結論

HC感染マウスを用いて種々の抗ウイルス剤の効果判定および新規治療法の開発が可能である．

F．健康危機情報

特になし

G．研究発表

1．論文発表

・Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, Aikata H, Takahashi S, Chayama K. A randomized trial of high-dose interferon-a-2b combined with ribavirin in patients with chronic hepatitis C. J Med Virol 81:640-9, 2009

・Noguchi C, Imamura M, Tsuge M, Hiraga N, Mori N, Miki D, Kimura T, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Chayama K. G to A hypermutation in hepatitis B virus and clinical course of patients with chronic hepatitis B. J Infect Dis 199:1599-607, 2009

・Abe H, Ochi H, Maekawa T, Hatakeyama T, Tsuge M, Kitamura S, Kimura T, Miki D, Mitsui F, Hiraga N, Imamura M, Fujimoto Y, Takahashi S, Nakamura Y, Kumada H, Chayama K. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B

virus infection. Hepatol Res 23,1159-68,2009

・Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 119:3226-35,2009

・Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ. Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry. Gastroenterology 137:673-81,2009

・Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 119:3226-35,2009

・Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, Tsuge M, Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, Chayama K. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol 51:1046-54,2009

2．学会発表

・今村道雄,平賀伸彦,茶山一彰.HCV Core、ISDRのアミノ酸変異とPEG-IFN+リバビリン療法の治療成績およびHCV感染モデルマウスを用いたウイルス学的検討. 第45回日本肝臓学会総会　神戸　平成21年6月4日.

・今村道雄，平賀信彦，茶山一彰. HCVのCore領域およびISDR変異からみた治療戦略. 第13回日本肝臓学会大会　京都　平成21年10月14日.

・Michio Imamura, Nobuhiko Hiraga, Eiji Iwao, et al. Telaprevir treatment to a human hepatocyte chimeric mouse with genetically engineered hepatitis C virus infection. 10th AASLD, Boston, 平成21年10月30日.

H．知的財産権の出願・登録状況

特になし

Ⅲ．　研究成果の刊行に関する一覧表

別紙５：研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, Tsuge M, Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, Chayama K.	Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice	J Hepatol	51	1046-54	2009
Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H.	Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice.	J Clin Invest	119	3226-35	2009
Abe H, Ochi H, Maekawa T, Hatakeyama T, Tsuge M, Kitamura S, Kimura T, Miki D, Mitsui F, Hiraga N, Imamura M, Fujimoto Y, Takahashi S, Nakamura Y, Kumada H, Chayama K.	Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection	Hepatol Res	39	1159-68	2009
Noguchi C, Imamura M, Tsuge M, Hiraga N, Mori N, Miki D, Kimura T, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Chayama K.	G to A hypermutation in hepatitis B virus and clinical course of patients with chronic hepatitis B	J Infect Dis	199	1599-607	2009
Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K.	Deletion of angiotensin II type I receptor reduces hepatic steatosis.	J Hepatol	50	1226-35	2009
Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ.	Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry.	Gastroenterology	137	673-81	2009
Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K	A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.	Nat Gane	41	591-5	2009
Tsukada H, Ochi H, Maekawa T, Abe H, Fujimoto Y, Tsuge M, Takahashi H, Kumada H, Kamatani N, Nakamura Y, Chayama K; the Hiroshima	A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C	Gastroenterology	136	1796-805	2009

Liver Study Group, and Toranomon Hospital					
Kubo S, Kataoka M, Tateno C, Yoshizato K, Kawasaki Y, Kimura T, Faure-Kumarl E, Palmer DJ, Ng P, Okamura H, Kasahara N	In Vivo Stable Transduction of Humanized Liver Tissue in Chimeric Mice via High-capacity Adenovirus-Lentivirus Hybrid Vector.	Hum Gene Ther.	21	40-50	2010
Ogawa T, Iizuka M, Sekiya Y, Yoshizato K, Ikeda K, Kawada N	Suppression of type I collagen production by microRNA-29b in cultured human stellate cells.	Biochem Biophys Res Commun	391(1)	316-21	2010
Yoshizato K, Tateno C	A human hepatocyte-bearingmouse: An animal model to predict drug metabolism and effectiveness in humans.	PPAR Research	2009	1-11	2009
Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, Tsuge M, Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, Chayama K.	Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.	J Hepatol	51(6)	1046-54	2009
Nishie M, Tateno C, Utoh R, Kohashi T, Masumoto N, Kobayashi N, Itamoto T, Tanaka N, Asahara T, Yoshizato K.	Hepatocytes from fibrotic liver possess high growth potential in vivo.	Cell Transplant.	18 (5)	665-675	2009
Yoshizato K, Tateno C	In vivo modeling of human liver for pharmacological study using humanized mouse.	Expert Opin Drug Metab Toxicol.	5(11)	1435-1446	2009
Noguchi C, Imamura M, Tsuge M, Hiraga N, Mori N, Miki D, Kimura T, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, Chayama K.	G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection.	J Infect Dis.	1;199 (11)	1599-1607	2009
Uno S, Endo K, Ishida Y, Tateno C, Makishima M, Yoshizato K, Nebert DW.	CYP1A1 and CYP1A2 expression: comparing 'humanized' mouse lines and wild-type mice; comparing human and mouse hepatoma-derived cell lines.	Toxicol Appl Pharmacol.	15; 237 (1)	119-126	2009
Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M.	Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.	Pancreas.	38 (4)	427-435	2009
Hodo Y, Hashimoto SI, Honda M, Yamashita T, Suzuki Y, Sugano S, Kaneko S, Matsushima K.	Comprehensive gene expression analysis of 5'-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma.	Genomics	(in press)		2010

Komura T, Sakai Y, Honda M, Takamura T, Matsushima K, Kaneko S.	CD14+monocytes are vulnerable and functionally impaired under ER stress in patients with type 2 diabetes.	Diabetes	(in press)		2009
Takatori H, Yamashita T, Honda M, Nishino R, Arai K, Yamashita T, Takamura H, Ohta T, Zen Y, Kaneko S.	dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma.	Liver Int	(in press)		2009
Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S.	Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma.	Hepatology	49(4)	1098-112	2009
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW.	EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.	Gastroenterology	136(3)	1012-24	2009
Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T, Kaneko S.	Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma.	J Hepatol	50(1)	100-10	2009
Hussein H. Aly, Yue Qi, Kimie Atsuzawa, Noobuteru Usuda, Yasutsugu Takada, Yasuhito Tanaka, Masashi Mizogami. Kunitada Shimotohno, Makoto Hijikata	Strain-dependent viral dynamics and virus cell interactions observed in a novel in vitro system supporting the life cycle of blood borne HCV.	Hepatology	50(3)	689-696	2009
Hussein H. Aly, Kunitada Shimotohno, Makoto Hijikata	3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV	Biochem. Biophys. Res. Commun.	244(9)	330-334	2009
Takayuki Murata, Yoshitaka Sato, Sanae Nakayama, Ayumi Kudoh, Satoko Iwahori, Hiroki Isomura, Masako Tajima, Takayuki Hishiki, Takayuki Ohshima, Makoto Hijikata, Kunitada Shimotohno, and Tatsuya Tsurumi	TORC 2, a coactivator of CREB, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein,	J. Biol. Chem.	46 (12)	1089-1097	2008
Kazuo Sugiyama, Kenji Suzuki, Takahide Nakazawa, Kenji Funami, Takayuki Hishiki, Kazuya Ogawa, Satoru Saito, Kumiko W. Shimotohno, Takeshi Suzuki, Yuko Shimizu, Seiri Tobita, Makoto Hijikata, Hiroshi Takaku, Kunitada Shimotohno	Genetic analysis of hepatitis C virus with defective genome and its infectivity in vitro.	J. Virol.	83(13)	6922-6928	2009

Kaku Goto, Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kunitada Shimotohno	Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.	Cancer Science	100 (10)	1943-1950	2009
Hattori K Nishikawa M, Watcharanurak K, Ikoma A Kabashima K, Toyota H, Takahashi Y, Takahashi R, Watanabe Y, Takakura Y.	Sustained exogenous expression of therapeutic levels of interferon-γ ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization	J Immunol	In press		2010
Yasuda S, Yoshida H, Nishikawa M, Takakura Y.	Comparison of the type of liposome involving cytokine production induced by non-CpG lipoplex in macrophages	Mol Pharm	In press		2010
Nishikawa M, Otsuki T, Ota A, Guan X, Takemoto S, Takahashi Y, Takakura Y.	Induction of tumor-specific immune response by gene transfer of Hsp70-cell penetrating peptide fusion protein to tumors in mice	Mol Ther	18	421-428	2010
Yoshida H, Nishikawa M, Yasuda S, Mizuno Y, Toyota H, Kiyota T, Takahashi R, Takakura Y.	TLR9-depdendent systemic interferon-beta production by intravenous injection of plasmid DNA/cationic liposome complex in mice	J Gene Med	11	708-717	2009
Takahashi Y, Nishikawa M, Takakura Y.	Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy	Adv Drug Delivery Rev	61	760-766	2009
Enomoto N, Maekawa S.	HCV genetic elements determining the early response to peginterferon and ribavirin therapy.	Intervirology.	53(1)	66-9	2010
Maekawa S, Enomoto N.	Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C	J Gastroenterol	44(10)	1009-15	2009
Itakura J, Kurosaki M, Itakura Y, Maekawa S, Asahina Y, Izumi N, Enomoto N.	Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model	Biosystems.	99(1)	70-8	2010
Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, Chen CH, Suda G, Mishima K, Onuki Y, Yamamoto M, Maekawa S, Enomoto N, Kanai T, Tsuchiya K, Watanabe M.	Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replication.	Hepatol Res.	39(1)	60-9.	2009
Taguwa S., Kambara H., Omori H., Tani H., Abe T., Mori Y., Suzuki T., Yoshimori T., Moriishi K., and Matsuura Y.	Co-chaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway.	Journal of Virology	83	10427-10436	2009

Yamashita T., Mori Y., Miyazaki N., Cheng H.R., Yoshimura M., Unno H., Shima R., Moriishi K., Tsukihara T., Li T.C., Takeda N., Miyamura T., and Matsuura Y.	Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure.	Proc. Natl. Acad. Sci. USA	106	12986-12991	2009
Kukihara H., Moriishi K., Taguwa S., Tani H., Abe T., Mori Y., Suzuki T., Fukuhara T., Taketomi A., Maehara Y., and Matsuura Y.	Human VAP-C negatively regulates hepatitis C virus propagation.	Journal of Virology	83	7959-7969	2009
Abe T., Kaname Y., Wen X., Tani H., Moriishi K., Uematsu S., Takeuchi O., Ishii K.J., Kawai T., Akira S., and Matsuura Y.	Baculovirus induces type I IFN production through TLR-dependent and -independent pathways in a cell type-specific manner.	Journal of Virology	83	7629-7640	2009
Moriya K., Miyoshi H., Tsutsumi T., Shinzawa S., Fujie H., Shintani Y., Yotsuyanagi H., Moriishi K., Matsuura Y., Suzuki T., Miyamura T., Koike K.	Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: analysis using mouse model and cultured cells.	Am. J. Pathol.	175	1515-1524	2009
Hara H., Aizaki H., Matsuda M., Shinkai-Ouchi F., Inoue Y., Murakami K., Shoji I., Kawakami H., Matsuura Y., Lai M.M., Miyamura T., Wakita T., and Suzuki T.	Involvement of creatine kinase B in hepatitis C virus genome replication through interaction with the viral NS4A protein.	Journal of Virology	83	5137-5147	2009
Suzuki R., Moriishi K., Fukuda K., Shirakura M. Ishii K., Shoji I., Wakita T., Miyamura T., Matsuura Y., and Suzuki T.	Proteasomal Turnover of Hepatitis C Virus Core Protein Is Regulated by Two Distinct Mechanisms: a Ubiquitin-Dependent Mechanism and a Ubiquitin-Independent but PA28-Dependent Mechanism.	Journal of Virology	83	2389-2392	2009
Mori K., Amano M., Takefuji M., Kato K., Morita Y., Nishioka T., Matsuura Y., Murohara T., Kaibuchi K.	Rho-kinase contributes to sustained RhoA activation through phosphorylation of p190A RhoGAP.	J. Biol. Chem.	284	5067-5076	2009
Noritake J., Fukata Y., Iwanaga T., Hosomi N., Tsutsumi R., Matsuda N., Tani H., Iwanari H., Mochizuki Y., Kodama T., Matsuura Y., Bredt D.S., Hamakubo T., Fukata M.	Mobile DHHC palmitoylating enzyme mediates activity-sensitive synaptic targeting of PSD-95.	J .Cell Biol.	186	147-160	2009
M.Ohira, K.Ishiyama, Y.Tanaka, M.Doskari, Y.Igarashi, H.Tashiro, N.Hiraga, M.Imamura,	Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and	The Journal of Clinical Investigation	119(11):	3226-3235	2009

N.Sakamotom K.Chayama, T.Asahara, H.Ohdan	humanized mice.				
H.Tahara, Y.Tanaka, K.Ishiyama, K. Ide, M.Shishida, T.Irei, Y.Ushitora, M.Ohira, M.Banshodani, H.Tashiro, T.Itamoto, T.Asahara, M.Imamura, S. Takahashi, K.Chayama, H.Ohdan	Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness.	Transpl Int	22(8)	805-813	2009
M.Ohira, M.Ishifuro, K.Ide, T.Irei, H.Tashiro, T.Itamoto, K.Ito, K. Chayama, T.Asahara, H.Ohdan	Significant correlation between spleen volume and thrombocytopenia in liver transplant patients: A concept for predicting persistent thrombocytopenia.	Liver Transplantation	15(2)	208-215	2009

Ⅳ．　研究成果の刊行物・別刷

ELSEVIER

Journal of Hepatology 51 (2009) 1046–1054

Journal of Hepatology

www.elsevier.com/locate/jhep

Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice☆

Nobuhiko Hiraga[1,2], Michio Imamura[1,2], Tsuyoshi Hatakeyama[1], Shosuke Kitamura[1], Fukiko Mitsui[1,b], Shinji Tanaka[1], Masataka Tsuge[1,2], Shoichi Takahashi[1,2], Hiromi Abe[2,3], Toshiro Maekawa[2,3], Hidenori Ochi[2,3], Chise Tateno[2,4], Katsutoshi Yoshizato[2,4,5], Takaji Wakita[6], Kazuaki Chayama[1,2,3,*]

[1] *Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan*
[2] *Liver Research Project Center, Hiroshima University, Hiroshima, Japan*
[3] *Laboratory for Liver Diseases, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan*
[4] *PhoenixBio Co., Ltd., Higashihiroshima, Japan*
[5] *Osaka City University Graduate School of Medicine, Osaka, Japan*
[6] *Department of Virology II, National Institute of Infectious Diseases, Shinjuku-ku, Japan*

***Background/Aims*: Both hepatitis B virus (HBV) and hepatitis C virus (HCV) replicate in the liver and show resistance against innate immunity and interferon (IFN) treatment. Whether there is interference between these two viruses is still controversial. We investigated the interference between these two viruses and the mode of resistance against IFN.**

***Methods*: We performed infection experiments with either or both of the two hepatitis viruses in human hepatocyte chimeric mice. Huh7 cell lines with stable production of HBV were also established and transfected with HCV JFH1 clone. Mice and cell lines were treated with IFN. The viral levels in mice sera and culture supernatants and messenger RNA levels of IFN-stimulated genes were measured.**

***Results*: No apparent interference between the two viruses was seen *in vivo*. Only a small (0.3 log) reduction in serum HBV and a rapid reduction in HCV were observed after IFN treatment, regardless of infection with the other virus. In *in vitro* studies, no interference between the two viruses was observed. The effect of IFN on each virus was not affected by the presence of the other virus. IFN-induced reductions of viruses in culture supernatants were similar to those in *in vivo* study.**

***Conclusions*: No interference between the two hepatitis viruses exists in the liver in the absence of hepatitis. The mechanisms of IFN resistance of the two viruses target different areas of the IFN system.**
© 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

***Keywords*: Superinfection; JFH-1; IFN-stimulated genes**

Received 4 February 2009; received in revised form 14 July 2009; accepted 15 July 2009; available online 23 September 2009
Associate Editor: F. Zoulim

☆ C.T. and K.Y. are employees of PhoenixBio Co. Ltd., Higashihiroshima, Japan. The other authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industry or conflict of interest with respect to this manuscript.

* Corresponding author. Tel.: +81 82 2575190; fax: +81 82 2556220.
E-mail address: chayama@hiroshima-u.ac.jp (K. Chayama).

Abbreviations: GAPDH, glyceraldehydes-3-phosphate dehydrogenase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; OAS, 2′,5′-oligoadenylate synthetase; PCR, polymerase chain reaction; SCID, severe combined immunodeficiency; uPA, urokinase-type plasminogen activator.

0168-8278/$36.00 © 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.jhep.2009.09.002

1. Introduction

Both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are serious health problems worldwide. More than 350 million people are infected with HBV, and more than 170 million people are infected with HCV [1,2]. Both types of hepatitis viruses result in the development of chronic liver infection and lead to death due to liver failure and hepatocellular carcinoma [3]. To date, interferon (IFN) remains one of the most important drugs available for the treatment of both types of hepatitis viral infections. Although it is assumed that IFN suppresses viral replication through the effect of IFN-induced gene products such as mixovirus resistance protein A (MxA), RNA-dependent protein kinase (PKR), and 2′,5′-oligoadenylate synthetase (OAS) [4], the precise mechanism of action of these proteins on both hepatitis viruses are unknown.

Coinfection with both viruses leads to a rapid and severe progression of chronic liver disease [5], with a higher risk of hepatocellular carcinoma [6]. Currently, there is a debate about whether or not there is interference between the two hepatitis viruses, with some favoring such interference [7] and others arguing against such a concept [8]. A number of mechanisms can cause interference between viruses. A major mechanism of interference is induction of IFN by one virus to prevent replication of the second virus; however, viruses develop their own strategies to resist the effect of IFN. In clinical practice, practitioners often perceive that reduction of HBV in serum by IFN therapy is poorer compared with HCV. HCV levels in sera of IFN-treated patients decrease relatively rapidly, and a proportion of patients eventually show complete eradication of the virus. Furthermore, the recent use of pegylated IFN (PEG-IFN) in combination with ribavirin has improved the eradication rate [9]. Eradication of HBV by IFN, however, is usually difficult, even when using IFN combined with ribavirin [10].

The mechanisms developed by viruses to resist host innate immunity, including IFN signaling, are well established in some viruses. Such mechanisms involve interruption of IFN signaling by interacting molecules that transduce the signal from the IFN receptor through the Janus kinase (Jak) signal transducer and activator of transcription (STAT) pathway [4]. Viral proteins of paramixoviruses, for example, inhibit IFN signaling [11]. Several studies have also examined the mechanisms by which HCV resists the host immune system. These include degradation of Cardif adaptor protein by NS3A/4 protease [12]. Generally, expression of HCV protein is associated with inhibition of STAT1 function independent of STAT tyrosine phosphorylation [13]. Additionally, expression of the HCV core protein in cultured cells is associated with increased expression levels of the suppressor of cytokine signaling 3 (SOCS-3) [14]. The NS5A and E2 proteins are both inhibitors of PKR [15]. These strong actions of HCV against innate immunity are consistent with the high chronicity rate of the virus. IFN, however, effectively reduces HCV replicon in Huh7 cells [16], suggesting that the virus has little potential to disturb the actions of IFN.

In contrast to HCV, the mechanisms of IFN resistance by HBV are poorly understood. To date, only a few studies have reported the molecular mechanisms of HBV resistance against the actions of IFN. The HBV-related resistance to IFN, for example, involves upregulation of protein phosphatase 2A (PP2A) as the primary event, which subsequently leads to inhibition of protein arginine methyltransferase 1 (PRMT1) and reduced STAT1 methylation [17]. In addition to these molecular mechanisms, microarray analyses of serial liver biopsies of experimentally infected chimpanzees showed striking differences in the early immune responses to HBV and HCV. HCV, for example, induced early changes in the expression of many intrahepatic genes, including genes involved in type 1 IFN response [18], whereas HBV did not induce any detectable changes in the expression of intrahepatic genes in the first weeks of infection [19].

HBV–HCV double infection is a good model to use for assessment of the mechanism of IFN resistance by these two viruses because one can test the effect of IFN on one virus in the presence of the other virus. Recently, Bellecave et al. [20] established a novel *in vitro* model system in Huh7 cells that allowed the analysis of both viruses in a replicating context and reported the absence of direct viral interference. To this end, we used human hepatocyte chimeric mice and cell culture systems in the present study. The results showed that the presence of HBV does not affect the actions of IFN on HCV and vice versa. These results suggest the lack of interference between the two viruses in liver cells and indicate that the reported interference between the two viruses might be via inflammation including death of infected cells by cytotoxic T cells, cytokines including IFN-α and IFN-β, and interleukins produced by hepatocytes and infiltrating T cells.

2. Materials and methods

2.1. Transfection of Huh7 cells with HBV DNA and HCV RNA

Huh7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum at 37 °C and under 5% CO_2. Cloning of HBV DNA and the plasmid construction were performed as described previously [21]. For production of stably transfected cell lines, Huh7 cells were seeded onto 90-mm-diameter culture dishes. Twenty micrograms of the plasmid pTRE-HB-wt [21] was transfected by the calcium phosphate precipitation method. Twenty-four hours after transfection, the cells were split and cultured in Hygromycin B-DMEM selection medium (300 μg/ml; Invitrogen Japan K.K., Osaka, Japan), while 50 colonies were isolated and cultured for identification of virus-producing cell lines. Clones positive

for both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were selected and further analyzed for production of HBV particles. Finally, three cell lines that produced more than 10^5 copies per milliliter of HBV DNA in supernatant were selected and used for further experiments.

For transfection with HCV RNA, we used pJFH1, which contains the complementary DNA of full-length genotype 2a HCV clone JFH1 downstream of the T7 promoter [22]. *In vitro* synthesis of HCV RNA and electroporation into Huh7 cells were performed as described previously [22,23]. Briefly, cells were treated with trypsin, washed twice with ice-cold RNase-free phosphate-buffered saline, and resuspended in Opti-MEM I (Invitrogen, Carlsbad, CA, USA) at a final concentration of 7.5×10^6 cells per milliliter. Then, 10 μg of HCV RNA to be electroporated was mixed with 0.4 mL of cell suspension and subjected to an electric pulse (950 μF and 260 V) using the Gene Pulser II Electroporation System (Bio-Rad, Hercules, CA, USA). After electroporation, the cell suspension was left for 5 min at room temperature and then incubated under normal culture conditions in a 10-cm-diameter cell culture dish.

2.2. Generation of human hepatocyte chimeric mice

Generation of the urokinase-type plasminogen activator $(uPA)^{+/+}$ and severe combined immunodeficiency $(SCID)^{+/+}$ mice and transplantation of human hepatocytes were performed as described recently by our group [21,23,24]. All mice were transplanted with frozen human hepatocytes obtained from the same donor. Infection, extraction of serum samples, and euthanasia were performed under ether anesthesia. The concentration of serum human serum albumin, which correlates with the repopulation index [24], was measured in mice as described previously [21]. All animal protocols described in this study were performed in accordance with the guidelines of the local committee for animal experiments. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.

2.3. Human serum samples

Human serum samples containing high titers of either HBV DNA (5.3×10^6 copies per milliliter) or genotype 1b HCV (2.2×10^6 copies per milliliter) were obtained from patients with chronic hepatitis with a written informed consent. The individual serum samples were divided into small aliquots and separately stored in liquid nitrogen until use. Chimeric mice were injected intravenously with 50 μL of either HBV- or HCV-positive human serum. Some mice were injected with HBV-positive human serum at 6 weeks after injection of HCV-positive human serum.

2.4. Analysis of HBV and HCV

HBsAg and HBeAg in culture supernatants were measured by commercially available enzyme-linked immunosorbent assay (ELISA) kits (Abbott Japan, Osaka, Japan). DNA was extracted from these samples by SMITEST (Genome Science Laboratories, Tokyo, Japan) and dissolved in 20 μL H_2O [21,25]. RNA was extracted from serum samples by Sepa Gene RV-R (Sankojunyaku, Tokyo), dissolved in 8.8 μL RNase-free H_2O, and reverse transcribed using random primer (Takara Bio Inc., Shiga, Japan) and M-MLV reverse transcriptase (ReverTra Ace, TOYOBO Co., Osaka, Japan) in a 20-μL reaction mixture according to the instructions provided by the manufacturer [23]. HCV core antigen in the culture medium was detected with HCV Ag assay (Ortho-Clinical Diagnostics, Rochester, NY, USA).

2.5. RNA extraction and measurement of mRNAs of interferon-induced genes by quantitative reverse transcription-polymerase chain reaction

Total RNA was extracted from cell lines using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). One nanogram of each RNA was reverse transcribed with ReverseTra Ace (TOYOBO Co.) and Random Primer (Takara Bio, Kyoto, Japan). We quantified the transcripts for MxA, OAS, and PKR. Amplification and detection were performed using ABI PRISM 7300 (Applied Biosystems, Foster City, CA, USA). Results were normalized to the transcript levels of glyceraldehydes-3-phosphate dehydrogenase (GAPDH).

2.6. Statistical analysis

Changes in HBV DNA and HCV RNA in mice sera were compared by Mann–Whitney test and unpaired *t* test. Differences in HBV DNA and HCV core antigen in mice sera and culture supernatants were analyzed by one-way analysis of variance followed by Scheffe's test. A *P* value of <0.05 was considered statistically significant.

3. Results

3.1. Infection of chimeric mouse with HBV and HCV and susceptibility to interferon

To investigate the interference between HBV and HCV and to examine the effect of IFN on both of these two viruses *in vivo*, we used six human chimeric mice. Each of six mice was inoculated intravenously with 50 μL of serum samples obtained from either HBV- or HCV-positive patients. The median HBV DNA level in HBV-positive serum-inoculated mice was 1.4×10^8 copies per milliliter (range: 5.3×10^6–3.6×10^9 copies per milliliter) at 6 weeks after inoculation (Fig. 1A), similar to our recent observation [21]. Similarly, the median HCV RNA level in HCV-positive human serum-inoculated mice was 1.0×10^7 copies per milliliter (range: 1.2×10^6–0.8×10^7 copies per milliliter) at 4 weeks after inoculation (Fig. 1B), as reported recently by our group [23]. Six weeks after inoculation, three of six HBV- or HCV-infected mice were treated daily with 7000 IU/g per day of intramuscular IFN-α for 2 weeks. Treatment resulted in a decrease of only 0.3 log in mice serum HBV DNA level compared to that in mice without treatment (Fig. 1A). In contrast, the same therapy resulted in a rapid decrease in HCV RNA to undetectable levels, as confirmed by quantitative polymerase chain reaction (PCR; Fig 1B).

To investigate the direct interference of the two viruses, we performed double-infection experiments. Ten chimeric mice were first inoculated intravenously with 50 μL of HCV-positive human serum samples. Six weeks after HCV infection when the mice developed HCV viremia, 50 μL of HBV-positive human serum samples were inoculated intravenously in 5 of 10 HCV-infected mice. All five mice became positive for both HBV and HCV at 2 weeks after HBV infection. No significant decrease in HCV RNA levels was observed in these superinfected mice before or after the development of HBV viremia (Fig. 2A). After HBV infection, there was no apparent decrease in HCV titer (Fig. 2B). Moreover, HBV DNA level in HBV–HCV-coinfected mice was comparable with that of only HBV-infected mice (Fig. 2B). These results sug-



Fig. 1. Changes in serum virus titers in mice inoculated with hepatitis B virus (HBV) – positive or hepatitis C virus (HCV) – positive human serum samples. (A) HBV DNA levels in six mice inoculated with HBV-positive serum samples. (B) HCV RNA levels in six mice inoculated with HCV-positive serum samples. Six weeks after inoculation, three of six mice were treated daily with (closed circles) or without (open circles) 7000 IU/g per day of interferon-alpha intramuscularly for 2 weeks. Mice serum samples were extracted every 2 weeks after inoculation. Data are mean plus or minus standard deviation ($n = 3$). The horizontal dashed line represents the detection limit (10^3 copies per milliliter).

gest no interference between the two viruses in mice, which lack immunocytes known to cause hepatitis.

To further investigate if infection with either of the two hepatitis viruses alters the effect of IFN against the other virus, three HBV–HCV-coinfected mice were treated with IFN-α (Fig. 3A). Such treatment resulted in a rapid decrease in HCV RNA in all mice to undetectable levels as confirmed by quantitative PCR (Fig. 3B). In contrast, no significant decrease in HBV DNA titers was observed in these mice (Fig. 3B). These results are similar to the reduction of HCV RNA and HBV DNA in mice that were infected with either of these hepatitis viruses. These results indicate that HCV is more susceptible to IFN-α than HBV and that each virus does not alter the effect of IFN on the other virus. Because the effect of IFN on HCV was not disturbed by HBV, we assumed that HBV has no effect on the signal from IFN receptor to IFN-stimulated genes. It is possible, however, that HBV and HCV replicated in different cells in these mice. Because it was impossible to detect HCV protein and RNA in HCV-infected mouse liver by histologic examination, we performed *in vitro* experiments.

3.2. Production of both HBV- and HCV-producing cells and the effect of interferon

To investigate the effect of IFN on HBV and HCV *in vitro*, we created cell lines that produce both HBV and HCV. First, we established stable HBV-producing Huh7 cell lines. Three cell lines (Clone-39, -42, and -53) that produced HBsAg, HBeAg, and HBV DNA into the supernatant were selected (Table 1). These cell lines continuously produced HBV for more than 3 months (data not shown). Next, JFH1 RNA was transfected into these HBV-producing cell lines to produce both HBV DNA and HCV proteins into the supernatant. HBV DNA levels in the supernatants of these cell lines decreased in Clone-39, increased in Clone-42, and did not change in Clone-53 after JFH1 transfection (Fig. 4A). In contrast, HCV core antigen levels in the supernatants were higher in two of the three cell lines (Clone-39 and -42) than in Huh7 cells, and the level was not different in the remaining cell line (Clone-53) (Fig. 4B). These results indicate that the production of each of the two viruses does not disturb the replication of the other virus.

3.3. Effects of interferon on HBV and HCV in vitro

The effects of IFN on virus production in both HBV- and HCV-producing cell lines was examined by adding different amounts of IFN-α (0, 50, and 500 IU/mL) into the culture. The mRNA levels of intracellular IFN-stimulated genes such as MxA, OAS, and PKR increased in a dose-dependent manner in all three cell lines as well as in parental Huh7 cells (Fig. 5A). Following the addition of IFN, no apparent reduction of HBV was noted in the supernatant of HBV–HCV-cotransfected cell lines (Fig. 5B). In contrast, the levels of HCV core antigen in the supernatant decreased in all three cell lines treated with IFN, and the decrease was dose-dependent (Fig. 5C).

4. Discussion

Although IFN treatment for chronic HCV infection has improved with the advent of PEG-IFN, the rate of viral eradication remains unsatisfactory [9]. The mechanism responsible for failure of IFN to eradicate the virus completely must be clarified. To study the mechanism of viral resistance against IFN, analysis of viral interference may give us some hints because one of the major mechanisms of interference is through the action of IFN.



Fig. 2. Comparison of hepatitis C virus (HCV) and hepatitis B virus (HBV) titers in experimentally infected mice. (A) Ten mice were inoculated with HCV-positive serum samples. Six weeks after HCV infection, 5 of the 10 mice were inoculated with HBV-positive human serum samples (closed circles). The remaining five mice (open circles) did not receive HBV inoculation. Data are mean plus or minus standard deviation ($n = 3$). (B) Serum HCV RNA titers in five mice infected with HCV before and at 6 weeks after HBV superinfection (left panel). Serum HBV DNA titers in five mice coinfected with HBV and HCV were compared with those of five mice with HBV infection only (Fig. 1) at 12 weeks after HCV inoculation (right panel). In these box-and-whisker plots, lines within the boxes represent the median values; the upper and lower lines of the boxes represent the 25th and 75th percentiles, respectively.

Accumulation of mononuclear cells is usually seen in the livers of infected individuals, in association with the state of inflammation. It is thus difficult to examine the interference of hepatitis viruses in infection and replication in liver cells without taking into consideration the effect of these immune cells as well as the chemokines and cytokines produced by these cells. Instead, the present study was designed to examine the interference between HBV and HCV in an experimental setup lacking such inflammatory interferences. The SCID-based human hepatocyte chimeric mouse model is ideal for investigating such interaction. We expected either reduction of HCV after inoculation of HBV in HCV-infected mice or failure to develop HBV viremia or low-level HBV viremia in these mice due to viral interference; however, no reduction in HCV titers occurred in these mice, and HBV infection developed in a manner similar to that in naïve mice (Fig. 2). We thus confirmed that there is no interference between the two viruses in the absence of immune reaction via the infiltrating lymphocytes in the liver.

Wieland et al. reported that HBV did not induce any genes during entry or expansion in HBV-infected chimpanzee livers and suggested that HBV was a stealthy virus early in the infection [19]. Because no reduction in HCV was noted during and after the development of high-level HBV viremia, we assume that HBV escapes innate immunity via an excellent mechanism without



Fig. 3. Changes in serum hepatitis C virus (HCV) RNA and hepatitis B virus (HBV) DNA levels and effects of IFN on HBV–HCV-coinfected mice. Three mice (mouse 1, 2, and 3) were inoculated with both HBV- and HCV-positive human serum samples and treated daily with 7000 IU/g per day of interferon-alpha (IFN-α) intramuscularly for 2 weeks. Mice sera samples were obtained every 2 weeks after injection, and HCV RNA (open circles) and HBV DNA (close circles) were analyzed by quantitative polymerase chain reaction. (A) The horizontal dashed line represents the detectable limit (10^3 copies per milliliter). (B) Serum HCV RNA and HBV DNA titers in mice before and after 2-week IFN-α treatment. In these box-and-whisker plots, lines within the boxes represent median values; the upper and lower lines of the boxes represent the 25th and 75th percentiles, respectively.

Table 1
Hepatitis B virus (HBV) markers in supernatants of stable HBV-transfected cell lines.

Clone	HBsAg (IU/L)	HBeAg (IU/L)	HBV DNA (log copies per milliliter)
39	0.46	4.57	5.2
42	8.16	1.34	5.3
53	0.08	9.29	5.4

Abbreviations: HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen.

evoking the IFN production system in liver cells. Further study using double-infected mice treated with anti-HBV nucleotide analogs and anti-HCV protease inhibitors should be conducted to confirm the present findings.

With regard to the use of IFN as a treatment, we initially assumed that HBV infection would prevent the effect of IFN on HCV and possibly vice versa in double-infection mice. Unexpectedly, the reduction of HCV by IFN therapy was quite similar in mice infected with HCV only and in those coinfected with HBV and HCV (Figs. 1 and 3). This finding indicated that HBV does not disturb the effect of IFN through signal transduction from the IFN receptor through the Jak-STAT pathway. It was, however, considered possible that HBV and HCV infect different liver cells in mice and replicated without being affected by each other. It has been reported that the same liver cell could be infected with both HBV and HCV [20,26], but it was difficult in the present study to confirm that these two viruses replicate in the same liver cell of mice because it is difficult to visualize HCV antigen and RNA in pathologic sections of the mouse liver. To address this issue, we transfected HCV to stable HBV-producing cell lines (Fig. 4). We thought that both HCV and HBV were produced from successfully HCV RNA transfected cells because transfected cells were stable HBV-producing cells. Presence of the both hepatitis viruses in the same hepatocytes has also been shown by a recent report by Bellecave et al. [20]. We showed in our cell line experiments that only HBV-transfected cell lines produced HBV and that cells cotransfected with HBV and HCV did not show a clear effect of HCV replication on HBV production (Fig. 4A). Similarly, stable production of HBV did not alter the replication of HCV (Fig. 4B). These data are consistent with a recent report [20] that showed that HCV could infect cells producing HBV and suggest a lack of interference between the two viruses in liver cells.

Using HCV-transfected HBV-producing cell lines, we demonstrated that presence of HBV did not disturb the actions of IFN on HCV (Fig. 5C). HCV utilizes certain machinery to disrupt the innate immune system; however, once exposed a large concentration of IFN, the virus shows high sensitivity, as shown in the replicon system [16,27]. Thus, HCV seems to have a relatively weak ability to disturb the antiviral actions of IFN compared with HBV. In contrast, HBV showed strong resistance against IFN in cells with diminished HCV replication [28]. The fact that HBV does not disturb IFN signaling but resists the actions of IFN suggests that HBV counteracts the actions of IFN at IFN-induced antiviral product levels.

Although the culture environment is different from the replicon system, the JFH1 strain seems relatively resistant to IFN [29]. This suggests that the core and envelope proteins, which are absent in the replicon system, might play a role in IFN resistance; however, we could not show any effect for HCV infection on the actions of IFN on HBV replication. This finding sug-



Fig. 4. Virus titers in supernatants of hepatitis B virus (HBV)–transfected or hepatitis C virus (HCV)–transfected cell lines. Huh7 cells were initially stably transfected with 1.4 genome-length HBV DNA. Three cell lines (Clone-39, -42, and -53) producing HBV DNA into the supernatant were selected. (A) HBV DNA levels in supernatants of HBV-producing cell lines 72 hours after transfection with JFH1 RNA (HCV positive) or control plasmid (HCV negative). (B) HCV core antigen levels in the supernatant of parental Huh7 cells and HBV-producing cell lines 72 h after transfection with JFH1 RNA. Data are mean plus or minus standard deviation (n = 3).



Fig. 5. Effects of interferon (IFN) treatment on hepatitis B virus (HBV) and hepatitis C virus (HCV) *in vitro*. Parental Huh7 cells and three HBV-transfected Huh7 cell lines (Clone-39, -42, and -53) were transfected with JFH1 RNA. Immediately after JFH1 transfection, the cell lines were treated with IFN-α (0, 50, and 500 IU/mL) for 72 h. (A) Intracellular gene expression levels of mixovirus resistance protein A (MxA), 2′,5′-oligoadenylate synthetase (OAS), and RNA-dependent protein kinase (PKR) were measured. RNA levels were expressed relative to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) messenger RNA. (B) HBV DNA and (C) HCV core antigen in supernatants were measured. Data are mean plus or minus standard deviation ($n = 3$).